Evaluation of the Pathways for Survivors Program to Address Breast Cancer Survivorship-Associated Distress: Survey Study.
anxiety
breast cancer
breast cancer survivors
cancer survivorship
depression
mental health
psychological health
quality of life
Journal
JMIR cancer
ISSN: 2369-1999
Titre abrégé: JMIR Cancer
Pays: Canada
ID NLM: 101666844
Informations de publication
Date de publication:
25 Feb 2022
25 Feb 2022
Historique:
received:
02
07
2021
accepted:
09
12
2021
revised:
04
11
2021
entrez:
25
2
2022
pubmed:
26
2
2022
medline:
26
2
2022
Statut:
epublish
Résumé
Patients with breast cancer frequently experience escalation of anxiety after completing curative treatment. This study evaluated the acceptability and psychological impact of a 1-day workshop to emphasize behavioral strategies involving intention and self-efficacy. Breast cancer survivors who attended a 1-day Pathways for Survivors workshop provided feedback and completed electronic quality of life (QOL) questionnaires at baseline, 1 and 6 weeks, and 6 months after the workshop. Attendees' baseline QOL scores were compared to follow-up (FUP) scores. Scores from patients receiving routine FUP care were also compiled as a reference population. In total, 77 patients attended 1 of 9 workshops. The mean satisfaction score was 9.7 out of 10 for the workshop and 9.96 out of 10 for the moderator. Participants' baseline mean Patient-Reported Outcomes Measurement Information System (PROMIS) anxiety and depression scores were 57.8 (SD 6.9) and 55.3 (SD 7.5), respectively, which were significantly higher than those of patients receiving routine FUP care (49.1, SD 8.3 and 47.3 SD 8.0, respectively). PROMIS anxiety and depression scores decreased, and the Happiness Index Profile (HIP-10) score-measuring intention and resiliency-increased significantly at 1- and 6-week FUPs. The Pathways for Survivors program was favorably received. Anxiety and depression decreased significantly at 1- and 6-weeks after the workshop and remained below baseline at 6 months. Increased HIP-10 scores suggest that patients acquired and implemented skills from the workshop. A 1-day workshop led by a lay moderator significantly improved several psychological measures, suggesting that it may be a useful and time-efficient strategy to improve QOL in breast cancer survivors. We are investigating whether an abbreviated "booster" of the intervention at a later date could further improve and maintain QOL gains.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with breast cancer frequently experience escalation of anxiety after completing curative treatment.
OBJECTIVE
OBJECTIVE
This study evaluated the acceptability and psychological impact of a 1-day workshop to emphasize behavioral strategies involving intention and self-efficacy.
METHODS
METHODS
Breast cancer survivors who attended a 1-day Pathways for Survivors workshop provided feedback and completed electronic quality of life (QOL) questionnaires at baseline, 1 and 6 weeks, and 6 months after the workshop. Attendees' baseline QOL scores were compared to follow-up (FUP) scores. Scores from patients receiving routine FUP care were also compiled as a reference population.
RESULTS
RESULTS
In total, 77 patients attended 1 of 9 workshops. The mean satisfaction score was 9.7 out of 10 for the workshop and 9.96 out of 10 for the moderator. Participants' baseline mean Patient-Reported Outcomes Measurement Information System (PROMIS) anxiety and depression scores were 57.8 (SD 6.9) and 55.3 (SD 7.5), respectively, which were significantly higher than those of patients receiving routine FUP care (49.1, SD 8.3 and 47.3 SD 8.0, respectively). PROMIS anxiety and depression scores decreased, and the Happiness Index Profile (HIP-10) score-measuring intention and resiliency-increased significantly at 1- and 6-week FUPs.
CONCLUSIONS
CONCLUSIONS
The Pathways for Survivors program was favorably received. Anxiety and depression decreased significantly at 1- and 6-weeks after the workshop and remained below baseline at 6 months. Increased HIP-10 scores suggest that patients acquired and implemented skills from the workshop. A 1-day workshop led by a lay moderator significantly improved several psychological measures, suggesting that it may be a useful and time-efficient strategy to improve QOL in breast cancer survivors. We are investigating whether an abbreviated "booster" of the intervention at a later date could further improve and maintain QOL gains.
Identifiants
pubmed: 35212641
pii: v8i1e31756
doi: 10.2196/31756
pmc: PMC8917438
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e31756Informations de copyright
©Saumya Umashankar, Matina Elise Mamounas, Madeline Matthys, Edward Kenji Hadeler, Emily Claire Wong, Greg Hicks, Jimmy Hwang, Amy Jo Chien, Hope S Rugo, Deborah Hamolsky, Laura Esserman, Michelle Melisko. Originally published in JMIR Cancer (https://cancer.jmir.org), 25.02.2022.
Références
Psychooncology. 2014 Jan;23(1):9-19
pubmed: 23897834
Patient Educ Couns. 2016 Mar;99(3):414-420
pubmed: 26456635
Br J Cancer. 2007 Dec 17;97(12):1625-31
pubmed: 18000503
JBI Database System Rev Implement Rep. 2015 Jan;13(1):112-21
pubmed: 26447012
Psychooncology. 2013 Sep;22(9):2059-63
pubmed: 23408595
Psychooncology. 2020 Mar;29(3):539-549
pubmed: 31785043
J Clin Psychol Med Settings. 2018 Dec;25(4):335-355
pubmed: 29480435
J Cancer Surviv. 2013 Sep;7(3):300-22
pubmed: 23475398
Psychooncology. 2009 Jan;18(1):71-8
pubmed: 18613299
J Cancer Surviv. 2010 Dec;4(4):361-71
pubmed: 20617394
Acta Oncol. 2017 Feb;56(2):314-320
pubmed: 28093034
J Behav Med. 2006 Feb;29(1):17-27
pubmed: 16400532
Behav Ther. 2008 Jun;39(2):126-36
pubmed: 18502246
J Natl Cancer Inst. 2012 Mar 7;104(5):386-405
pubmed: 22271773
J Psychosom Res. 2013 Apr;74(4):346-53
pubmed: 23497838
J Clin Oncol. 2017 Jul 1;35(19):2173-2183
pubmed: 28471726
Am Psychol. 2001 Mar;56(3):218-26
pubmed: 11315248
Palliat Support Care. 2006 Sep;4(3):219-37
pubmed: 17066964
Am Psychol. 2015 Feb-Mar;70(2):159-74
pubmed: 25730722
Health Qual Life Outcomes. 2003 May 01;1:16
pubmed: 12756054
Support Care Cancer. 2019 Mar;27(3):771-781
pubmed: 30488223
J Clin Oncol. 2020 Mar 1;38(7):734-743
pubmed: 31834818
J Natl Cancer Inst. 2018 Dec 1;110(12):1311-1327
pubmed: 30403799